Magnetically controlled transdermal delivery of gemcitabine via xanthan gum-coated magnetic nanoparticles embedded in gellan gum cryogel

Journal article


Authors/Editors


Strategic Research Themes


Publication Details

Author listManiwongwichit N., Morarad R., Sakunpongpitiporn P., Parinyanitikul N., Paradee N., Sirivat A.

PublisherElsevier

Publication year2024

JournalMaterials Chemistry and Physics: Including Materials Science Communications (0254-0584)

Volume number326

ISSN0254-0584

eISSN1879-3312

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85200891579&doi=10.1016%2fj.matchemphys.2024.129836&partnerID=40&md5=1ef07b2aff5d0c6446066626ca0b7df1

LanguagesEnglish-Great Britain (EN-GB)


View on publisher site


Abstract

Chemotherapy is a commonly used treatment for breast cancer, but it often causes significant side effects due to the high drug dosage required for injection or infusion administration. Transdermal drug delivery offers a non-invasive and controlled release approach. In this work, a novel approach was developed for using gellan gum as a drug matrix and Gemcitabine loaded xanthan gum coated Fe3O4 magnetic nanoparticles (Gem: Xan (1%v/v)Fe3O4) as a drug carrier complex. The magnetization values were found to be 84.69 emu/g, 16.63 emu/g, and 9.91 emu/g for Fe3O4, Xan (1%v/v)Fe3O4, and Gem: Xan (1%v/v)Fe3O4, respectively. Notably, this work showcases the synthesis of Gemcitabine loaded xanthan gum coated magnetic nanoparticles as a new drug carrier complex, explores the drug release kinetics, and demonstrates the biocompatibility and non-toxicity of gellan gum on human skin, offering promising implications for transdermal drug delivery. The Gemcitabine release was 54 % without magnetic nanoparticles, and it increased to 82 % with the incorporation of magnetic nanoparticles. The Gemcitabine release – permeation of Gem: Xan (1%v/v)Fe3O4 was higher than that of the pristine Gemcitabine permeation by 72 %. The experimental results revealed that the magnetic field played a crucial role in controlling the drug release rate, amount, and duration during the release and release-permeation study. © 2024 Elsevier B.V.


Keywords

Gemcitabine


Last updated on 2024-18-12 at 00:00